Actavis Inks $1.1M Deal In ADHD Medication Antitrust Suit

By Melissa Angell (May 25, 2021, 8:46 PM EDT) -- A proposed class of parents and caregivers who've accused Actavis of violating antitrust laws by delaying alternatives to its attention deficit hyperactivity disorder medication Intuniv have asked a Massachusetts federal judge to preliminarily approve a $1.1 million settlement with the drugmaker.

In a 17-page motion for preliminary approval filed Monday, class counsel explained that Actavis will dole out $1.1 million as a settlement payment to the indirect purchaser class. Members of the settlement class would be able to receive payments proportionate to the amount of tablets of brand-name or generic Intuniv that they purchased from November 2012 to the present....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!